U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Docket Number (Optional) TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING

REJECTION OVER A "PRIOR" PATENT	17500CON (BO1)
In re Application of: Stephen Donovan	
Application No.: 10/806,972	
Filed: 03/22/2004	
For: Botulinum Toxin Therapy for Neuropsychiatric Disorders	
The owner*, Allergan, Inc	
expires for failure to pay a maintenance fee; is held unenforceable; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened.	by any terminal disclaimer.
Check either box 1 or 2 below, if appropriate.	
For submissions on behalf of a business/organization (e.g., corporation, partnership, universi etc.), the undersigned is empowered to act on behalf of the business/organization.	ly, government agency,
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
2. V The undersigned is an attorney or agent of record, Reg. No. 33,433	
Sylven Parath Signature	9/28/A
Stephen Donovan	//////////////////////////////////////
Typed or printed name	
	714-246-4026
Terminal disclaimer fee under 37 CFR 1.20(d) included.	Telephone Number
WARNING: Information on this form may become public. Credit card inform be included on this form. Provide credit card information and authorization	nation should not n on PTO-2038.
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.